These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 11987436

  • 21. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden.
    Jönsson L.
    Am J Geriatr Pharmacother; 2005 Jun; 3(2):77-86. PubMed ID: 16129384
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Interferon beta-1b and secondary progressive multiple sclerosis: licence extension. Useful, but further assessment required.
    Prescrire Int; 2000 Aug; 9(48):110-1. PubMed ID: 11067719
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States.
    Rein DB, Wittenborn JS, Lee PP, Wirth KE, Sorensen SW, Hoerger TJ, Saaddine JB.
    Ophthalmology; 2009 May; 116(5):823-32. PubMed ID: 19285730
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression. First estimates.
    Brown MG, Murray TJ, Sketris IS, Fisk JD, LeBlanc JC, Schwartz CE, Skedgel C.
    Int J Technol Assess Health Care; 2000 May; 16(3):751-67. PubMed ID: 11028131
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Interferon β-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up.
    Tur C, Montalban X, Tintoré M, Nos C, Río J, Aymerich FX, Brieva L, Téllez N, Perkal H, Comabella M, Galán I, Calle D, Sastre-Garriga J, Rovira A.
    Arch Neurol; 2011 Nov; 68(11):1421-7. PubMed ID: 22084124
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life.
    Parkin D, Jacoby A, McNamee P, Miller P, Thomas S, Bates D.
    J Neurol Neurosurg Psychiatry; 2000 Feb; 68(2):144-9. PubMed ID: 10644777
    [Abstract] [Full Text] [Related]

  • 35. Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started?
    Lonergan R, Kinsella K, Duggan M, Jordan S, Hutchinson M, Tubridy N.
    Mult Scler; 2009 Dec; 15(12):1528-31. PubMed ID: 19995848
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Potential health care cost savings associated with early treatment of multiple sclerosis using disease-modifying therapy.
    Curkendall SM, Wang C, Johnson BH, Cao Z, Preblick R, Torres AM, Knappertz V, Gondek K.
    Clin Ther; 2011 Jul; 33(7):914-25. PubMed ID: 21684600
    [Abstract] [Full Text] [Related]

  • 39. [Limited effect of interferon-beta for the treatment of secondary progressive multiple sclerosis].
    Schreiber K, Voldsgaard A, Sørensen PS.
    Ugeskr Laeger; 2013 May 06; 175(19):1342-4. PubMed ID: 23663372
    [Abstract] [Full Text] [Related]

  • 40. Modelling disease progression in relapsing-remitting onset multiple sclerosis using multilevel models applied to longitudinal data from two natural history cohorts and one treated cohort.
    Tilling K, Lawton M, Robertson N, Tremlett H, Zhu F, Harding K, Oger J, Ben-Shlomo Y.
    Health Technol Assess; 2016 Oct 06; 20(81):1-48. PubMed ID: 27817792
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.